Stem definition | Drug id | CAS RN |
---|---|---|
hypnotics, barbituric acid derivatives | 2095 | 76-74-4 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
0.10 | g | P |
0.10 | g | R |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 12.61 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.91 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.47 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.39 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 22 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 19, 1973 | FDA | OAK PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Propofol infusion syndrome | 135.65 | 86.55 | 21 | 789 | 745 | 50603569 |
Mitochondrial DNA mutation | 125.21 | 86.55 | 17 | 793 | 233 | 50604081 |
Gene mutation | 111.19 | 86.55 | 19 | 791 | 1252 | 50603062 |
Blood gases abnormal | 94.51 | 86.55 | 15 | 795 | 624 | 50603690 |
Drug ineffective for unapproved indication | 87.46 | 86.55 | 26 | 784 | 21255 | 50583059 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective for unapproved indication | 151.60 | 82.42 | 44 | 1060 | 31089 | 64466539 |
Mitochondrial DNA mutation | 123.42 | 82.42 | 17 | 1087 | 242 | 64497386 |
Propofol infusion syndrome | 118.49 | 82.42 | 21 | 1083 | 1596 | 64496032 |
Gene mutation | 100.50 | 82.42 | 19 | 1085 | 2063 | 64495565 |
Drug ineffective | 88.33 | 82.42 | 88 | 1016 | 840159 | 63657469 |
Blood gases abnormal | 87.01 | 82.42 | 15 | 1089 | 968 | 64496660 |
None
Source | Code | Description |
---|---|---|
ATC | N05CA01 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Barbiturates, plain |
MeSH PA | D000759 | Adjuvants, Anesthesia |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D018682 | GABA Agents |
MeSH PA | D018757 | GABA Modulators |
MeSH PA | D006993 | Hypnotics and Sedatives |
MeSH PA | D018377 | Neurotransmitter Agents |
CHEBI has role | CHEBI:91016 | GABAA receptor agonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
General anesthesia | indication | 50697003 | |
Severe anxiety (panic) | indication | 80583007 | |
Epilepsy | indication | 84757009 | DOID:1826 |
Seizure disorder | indication | 128613002 | |
Insomnia | indication | 193462001 | |
Status epilepticus | indication | 230456007 | DOID:1824 |
Cerebral ischemia | indication | 287731003 | |
Local anesthesia | indication | 386761002 | |
Tetanus Adjunct Treatment | indication | ||
Benign intracranial hypertension | off-label use | 68267002 | DOID:11459 |
Apnea | contraindication | 1023001 | |
Suicidal thoughts | contraindication | 6471006 | |
Alcoholism | contraindication | 7200002 | |
Hyperammonemia | contraindication | 9360008 | |
Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Depressive disorder | contraindication | 35489007 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Hyperactive behavior | contraindication | 44548000 | |
Low blood pressure | contraindication | 45007003 | |
Heart disease | contraindication | 56265001 | DOID:114 |
Hepatic failure | contraindication | 59927004 | |
Substance abuse | contraindication | 66214007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Decreased respiratory function | contraindication | 80954004 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Pneumonia | contraindication | 233604007 | DOID:552 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Sleep automatism | contraindication | 247962006 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Respiratory insufficiency | contraindication | 409623005 | |
Porphyria | contraindication | 418470004 | |
Acute exacerbation of asthma | contraindication | 708038006 |
Species | Use | Relation |
---|---|---|
Cats | General anesthesia | Indication |
Dogs | General anesthesia | Indication |
Dogs | Strychnine poisoning | Indication |
Dogs | Euthanasia | Indication |
Horses | General anesthesia | Indication |
Horses | Sedative-relaxant | Indication |
Product | Applicant | Ingredients |
---|---|---|
Somnopentyl Injection | Intervet Inc. | 1 |
Combuthal Powder | Bimeda Animal Health Limited | 2 |
Chloropent | Zoetis Inc. | 3 |
Beuthanasia-D Special | Intervet Inc. | 2 |
Euthasol | Virbac AH Inc. | 2 |
Euthanasia-III Solution | Med-Pharmex Inc. | 2 |
Pentobarbital Sodium and Phenytoin Sodium | Akorn Animal Health Inc. | 2 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.81 | acidic |
pKa2 | 9.51 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Gamma-aminobutyric acid receptor subunit beta-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | IC50 | 4.06 | CHEMBL | CHEMBL | |||
GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | EC50 | 4.30 | WOMBAT-PK | CHEMBL | |||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 2.55 | WOMBAT-PK | |||||
GABA A receptor alpha-2/beta-2/gamma-2 | Ion channel | EC50 | 4.30 | CHEMBL | |||||
GABA-A receptor; anion channel | Ion channel | IC50 | 5.77 | CHEMBL |
ID | Source |
---|---|
4018516 | VUID |
N0000146838 | NUI |
D00499 | KEGG_DRUG |
24876-35-5 | SECONDARY_CAS_RN |
57-33-0 | SECONDARY_CAS_RN |
4018036 | VANDF |
4018516 | VANDF |
C0030883 | UMLSCUI |
CHEBI:7983 | CHEBI |
RAV | PDB_CHEM_ID |
CHEMBL448 | ChEMBL_ID |
DB00312 | DRUGBANK_ID |
CHEMBL971 | ChEMBL_ID |
D010424 | MESH_DESCRIPTOR_UI |
4737 | PUBCHEM_CID |
703 | INN_ID |
5480 | IUPHAR_LIGAND_ID |
I4744080IR | UNII |
203085 | RXNORM |
2161 | MMSL |
3697 | MMSL |
5253 | MMSL |
5254 | MMSL |
71886 | MMSL |
d00335 | MMSL |
001411 | NDDF |
001412 | NDDF |
33231001 | SNOMEDCT_US |
372703009 | SNOMEDCT_US |
66843009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-181 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-181 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-010 | INJECTION, SOLUTION | 50 mg | INTRAMUSCULAR | ANDA | 24 sections |
pentobarbital sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-676 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | ANDA | 26 sections |
Nembutal Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76478-501 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
Nembutal Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76478-501 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |